Kite Pharma, Inc. – Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma

Access Program Information

This is a multicenter, open-label expanded access protocol for the treatment of subjects
with relapsed/refractory transplant ineligible aggressive NHL.